Viral Conjunctivitis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Viral Conjunctivitis - Pipeline Review, H2 2016

Viral Conjunctivitis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Viral Conjunctivitis - Pipeline Review, H2 2016
Published Aug 17, 2016
42 pages — Published Aug 17, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Viral Conjunctivitis - Pipeline Review, H2 2016, provides an overview of the Viral Conjunctivitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Viral Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis
- The report reviews pipeline therapeutics for Viral Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Viral Conjunctivitis therapeutics and enlists all their major and minor projects
- The report assesses Viral Conjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Viral Conjunctivitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Viral Conjunctivitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Viral Conjunctivitis pipeline

  
Source:
Document ID
GMDHC8361IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Viral Conjunctivitis Overview61
Therapeutics Development71
  Pipeline Products for Viral Conjunctivitis Overview71
Viral Conjunctivitis Therapeutics under Development by Companies81
Viral Conjunctivitis Pipeline Products Glance92
  Clinical Stage Products91
  Early Stage Products101
Viral Conjunctivitis Products under Development by Companies111
Viral Conjunctivitis Companies Involved in Therapeutics Development125
  Adenovir Pharma AB121
  NanoViricides, Inc.131
  Panoptes Pharma Ges.m.b.H.141
  Shire Plc151
  Starpharma Holdings Limited161
Viral Conjunctivitis Therapeutics Assessment178
  Assessment by Monotherapy Products171
  Assessment by Target182
  Assessment by Mechanism of Action202
  Assessment by Route of Administration222
  Assessment by Molecule Type241
Drug Profiles2511
  APD-209 Drug Profile252
  APD-514 Drug Profile271
  astodrimer Drug Profile284
  EKCCide-I Drug Profile321
  PP-001 Drug Profile331
  SHP-640 Drug Profile342
Viral Conjunctivitis Dormant Projects361
Viral Conjunctivitis Discontinued Products371
Viral Conjunctivitis Product Development Milestones383
  Featured News &Press Releases381
    May 13, 2013: Starpharma's Dendrimer SPL7013 Demonstrates Potential As Viral Conjunctivitis Treatment381
    Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis381
    Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjuntivitis391
    May 05, 2010: Foresight Biotherapeutics, Inc 's Drug FST-100 Reduces Infectious Adenoviral Titers And Improves Clinical Signs in Conjunctivitis Model392
Appendix412
  Methodology411
  Coverage411
  Secondary Research411
  Primary Research411
  Expert Panel Validation411
  Contact Us411
  Disclaimer421

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Viral Conjunctivitis - Pipeline Review, H2 2016" Aug 17, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Viral-Conjunctivitis-Pipeline-Review-H2-2016-2088-16388>
  
APA:
Global Markets Direct - Market Research. (2016). Viral Conjunctivitis - Pipeline Review, H2 2016 Aug 17, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Viral-Conjunctivitis-Pipeline-Review-H2-2016-2088-16388>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.